PRRT: Identikit of the Perfect Patient

Overview

Journal Rev Endocr Metab Disord

Publisher Springer

Specialty Endocrinology

Date 2020 Sep 26

PMID 32978685

Citations 14

Authors

M Albertelli

A Dotto

C Di Dato

P Malandrino

R Modica

A Versari

A Colao

D Ferone

A Faggiano

Affiliations

Soon will be listed here.

Abstract

Peptide receptor radionuclide therapy (PRRT) has been strengthened since the publication of NETTER-1. Nevertheless, the correct positioning in the therapeutic algorithm is debated, and no optimal sequence has yet been standardized. Possible criteria to predict the response to PRRT in neuroendocrine tumors (NET) have been proposed. The aim of this review is to define the perfect identity of the eligible patient who can mostly benefit from this therapy. Possible predictive criteria which have been analysed were: primary tumor site, grading, tumor burden, FDG PET and Ga-PET uptake. Primary tumor site and Ga-PET uptake do not play a pivotal role in predicting the response, while tumor burden, FDG PET uptake and grading seem to represent predictive/prognostic factors for response to PRRT. The heterogeneity in trial designs, patient populations, type of radionuclides, previous therapies and measurement of outcomes, inevitably limits the strength of our conclusions, therefore care must be taken in applying these results to clinical practice. In conclusion, the perfect patient, selected by Ga-PET uptake, will likely have a relatively limited liver tumor burden, a ki67 index <20% and will respond to PRRT irrespective to primary tumor. Nevertheless, we have mostly prognostic than predictive factors to predict the efficacy of PRRT in individual patients, while a promising tool could be the NETest. However, to date, the identikit of the perfect patient for PRRT is a puzzle without some pieces and still we cannot disregard a multidisciplinary discussion of the individual case to select the patients who will mostly benefit from PRRT.

Citing Articles

Non-[F]FDG PET-Radiopharmaceuticals in Oncology.

Dimitrakopoulou-Strauss A, Pan L, Sachpekidis C Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770483 PMC: 11677833. DOI: 10.3390/ph17121641.

Organ-specific response to [Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [Ga]DOTATOC PET/CT in patients with metastatic small intestine neuroendocrine tumors.

Bessac D, Baltzinger P, Poterszman N, Pham Van F, Collen C, Malouf G Endocrine. 2024; 87(3):1333-1341.

PMID: 39714577 DOI: 10.1007/s12020-024-04138-y.

Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.

Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B EJNMMI Res. 2024; 14(1):110.

PMID: 39557730 PMC: 11574229. DOI: 10.1186/s13550-024-01163-w.

Retrospective evaluation of the predictive value of tumour burden at baseline [ Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT.

Galne A, Sundlov A, Enqvist O, Sjogreen Gleisner K, Larsson E, Tragardh E EJNMMI Rep. 2024; 8(1):24.

PMID: 39112915 PMC: 11306659. DOI: 10.1186/s41824-024-00210-y.

Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms.

Reccia I, Pai M, Kumar J, Spalding D, Frilling A Cancers (Basel). 2023; 15(6).

PMID: 36980746 PMC: 10047148. DOI: 10.3390/cancers15061861.

References

Aalbersberg E, Huizing D, Walraven I, de Wit-van der Veen B, Kulkarni H, Singh A . Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients. J Nucl Med. 2019; 60(9):1259-1265. DOI: 10.2967/jnumed.118.224386. View

Adnan A, Kudachi S, Ramesh S, Prabhash K, Basu S . Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors. Nucl Med Commun. 2019; 40(9):947-957. DOI: 10.1097/MNM.0000000000001054. View

Alexandraki K, Tsoli M, Kyriakopoulos G, Angelousi A, Nikolopoulos G, Kolomodi D . Current concepts in the diagnosis and management of neuroendocrine neoplasms of unknown primary origin. Minerva Endocrinol. 2019; 44(4):378-386. DOI: 10.23736/S0391-1977.19.03012-8. View

Baum R, Kluge A, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N . [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics. 2016; 6(4):501-10. PMC: 4775860. DOI: 10.7150/thno.13702. View

Baum R, Kulkarni H, Singh A, Kaemmerer D, Mueller D, Prasad V . Results and adverse events of personalized peptide receptor radionuclide therapy with Yttrium and Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018; 9(24):16932-16950. PMC: 5908296. DOI: 10.18632/oncotarget.24524. View

Bodei L, Cremonesi M, Grana C, Fazio N, Iodice S, Baio S . Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011; 38(12):2125-35. DOI: 10.1007/s00259-011-1902-1. View

Bodei L, Kidd M, Modlin I, Severi S, Drozdov I, Nicolini S . Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2015; 43(5):839-851. DOI: 10.1007/s00259-015-3250-z. View

Bodei L, Kidd M, Singh A, van der Zwan W, Severi S, Drozdov I . PRRT genomic signature in blood for prediction of Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging. 2018; 45(7):1155-1169. PMC: 6716527. DOI: 10.1007/s00259-018-3967-6. View

10.

Brabander T, van der Zwan W, Teunissen J, Kam B, Feelders R, de Herder W . Long-Term Efficacy, Survival, and Safety of [Lu-DOTA,Tyr]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017; 23(16):4617-4624. DOI: 10.1158/1078-0432.CCR-16-2743. View

11.

Bushnell Jr D, ODorisio T, ODorisio M, Menda Y, Hicks R, Van Cutsem E . 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010; 28(10):1652-9. PMC: 4872330. DOI: 10.1200/JCO.2009.22.8585. View

12.

Campana D, Capurso G, Partelli S, Nori F, Panzuto F, Tamburrino D . Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging. 2013; 40(8):1197-205. DOI: 10.1007/s00259-013-2402-2. View

13.

Carlsen E, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana C . Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2018; 26(2):227-239. DOI: 10.1530/ERC-18-0424. View

14.

Cwikla J, Sankowski A, Seklecka N, Buscombe J, Nasierowska-Guttmejer A, Jeziorski K . Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2009; 21(4):787-794. DOI: 10.1093/annonc/mdp372. View

15.

Delpassand E, Samarghandi A, Zamanian S, Wolin E, Hamiditabar M, Espenan G . Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014; 43(4):518-25. DOI: 10.1097/MPA.0000000000000113. View

16.

Demirci E, Kabasakal L, Toklu T, Ocak M, Sahin O, Alan-Selcuk N . 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. Nucl Med Commun. 2018; 39(8):789-796. DOI: 10.1097/MNM.0000000000000874. View

17.

Dumont R, Seiler D, Marincek N, Brunner P, Radojewski P, Rochlitz C . Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. Am J Nucl Med Mol Imaging. 2015; 5(1):46-55. PMC: 4299770. View

18.

Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S . Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2010; 38(3):459-66. DOI: 10.1007/s00259-010-1610-2. View

19.

Ezziddin S, Sabet A, Heinemann F, Yong-Hing C, Ahmadzadehfar H, Guhlke S . Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J Nucl Med. 2011; 52(8):1197-203. DOI: 10.2967/jnumed.111.090373. View

20.

Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A . Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014; 41(5):925-33. DOI: 10.1007/s00259-013-2677-3. View

21.

Ezziddin S, Attassi M, Yong-Hing C, Ahmadzadehfar H, Willinek W, Grunwald F . Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014; 55(2):183-90. DOI: 10.2967/jnumed.113.125336. View